CLAIMS

1. A method for treating obsessive-compulsive disorder in a patient in need thereof, comprising administering to the patient a dosage form comprising an effective amount of troriluzole.

2. The method of Claim 1, wherein the dosage form is administered daily for four weeks or longer, and wherein the patient at week 4 has a mean Y-BOCS total scale change of at least -3.4 points from baseline.

3. The method of Claim 1, wherein the dosage form is administered daily for four weeks or longer, and wherein the patient at week 4 has a mean Y-BOCS total scale change of at least 0.5 points compared to placebo.

4. The method of Claim 1, wherein the dosage form is administered daily for eight weeks or longer, and wherein at week 8 the patient has a mean Y-BOCS total scale change of at least -5.1 points from baseline.

5. The method of Claim 1, wherein the dosage form is administered daily for eight weeks or longer, and wherein the patient at week 8 has a mean Y-BOCS total scale change of at least 1.5 points compared to placebo.

6. The method of Claim 1, wherein the dosage form is administered daily for twelve weeks or longer, and wherein at week 12 the patient has a mean Y-BOCS total scale change of -5.9 points from baseline.

7. The method of Claim 1, wherein the dosage form is administered daily for twelve weeks or longer, and wherein the patient at week 12 has a mean Y-BOCS total scale change of 1.0 points compared to placebo.

8. The method of Claim 1, wherein the patient has a median Y-BOCS score of 26 or greater.

9. The method of Claim 8, wherein the dosage form is administered daily for four weeks or longer, and wherein the patient at week 4 has a mean Y-BOCS total scale change of at least -4.1 points from baseline.

10. The method of Claim 8, wherein the dosage form is administered daily for four weeks or longer, and wherein the patient at week 4 has a mean Y-BOCS total scale change of at least 0.6 points compared to placebo.

11. The method of Claim 8, wherein the dosage form is administered daily for eight weeks or longer, and wherein at week 8 the patient has a mean Y-BOCS total scale change of at least -6.0 points from baseline.

12. The method of Claim 8, wherein the dosage form is administered daily for eight weeks or longer, and wherein the patient at week 8 has a mean Y-BOCS total scale change of at least 2.9 points compared to placebo.

13. The method of Claim 8, wherein the dosage form is administered daily for twelve weeks or longer, and wherein at week 12 the patient has a mean Y-BOCS total scale change of -7.0 points from baseline.

14. The method of Claim 8, wherein the dosage form is administered daily for twelve weeks or longer, and wherein the patient at week 12 has a mean Y-BOCS total scale change of 2.4 points compared to placebo.

15. A dosage form comprising troriluzole in an amount effective to treat obsessive-compulsive disorder in a patient in need thereof.

16. The dosage form of Claim 15, comprising troriluzole in an amount of 200 mg or greater.

17. The dosage form of Claim 15, comprising troriluzole in an amount of 250 mg or greater.

18. The dosage form of Claim 15, comprising troriluzole in an amount of 300 mg or greater.

19. The dosage form of Claim 15, comprising troriluzole in an amount of 350 mg or greater.

20. The dosage form of Claim 15, comprising troriluzole in an amount of 400 mg or greater.

21. The dosage form of Claim 15, comprising troriluzole in an amount of 450 mg or greater.

22. The dosage form of Claim 15, comprising troriluzole in an amount of 500 mg or greater.